How many units of retatrutide should I take?

Last updated 2026-07-25

Why isn't there a standard retatrutide dose in units?

Because there's no approved retatrutide product to standardize a dose from. A search of Drugs@FDA, the FDA's own database of every approved drug product, returns nothing for the generic name retatrutide ^[1]. No FDA approval means no FDA-approved label, no FDA-approved dosing table, and no FDA-approved concentration to convert into syringe units. The question "how many units should I take" assumes retatrutide is a settled medication like insulin, where a nurse can tell you 10 units means a specific, standardized dose. It isn't. What exists instead is trial data reported in milligrams, plus a gray market where people are guessing at concentrations from vials with no certificate of analysis behind them. Those are two very different things, and conflating them is how people end up dosing wrong. If you're seeing "units" language at all, it's almost certainly coming from a compounding or reconstitution context (converting a milligram dose into insulin-syringe units after mixing powder with bacteriostatic water). That math is worth understanding structurally, which is why we cover it separately in our reconstitution guide and dosage calculator, but doing that math on a product with no legal status doesn't make the underlying substance any safer or more legal to use.

What doses did the actual clinical trials use?

The published phase 2 obesity trial (NCT04881760, development code LY3437943) tested weekly subcutaneous injections at several fixed dose levels, escalated gradually, with the top studied dose at 12 mg once weekly ^{[2] [3]}. At 48 weeks, the 12 mg group averaged 24.2% weight loss compared with 2.1% for placebo ^[2]. Lower dose arms were also tested in the same trial and produced smaller, dose-dependent effects. That 24.2% figure is the number that made headlines, and it's real, but it came from a specific weekly milligram amount, delivered under medical supervision, with lab monitoring, dose titration schedules, and a research protocol behind it. It did not come from someone drawing an estimated number of units into a syringe at home based on a vendor's suggested regimen. Retatrutide has also moved into type 2 diabetes trials and additional later-phase obesity trials, including NCT05929066 and NCT05882045, which list their own enrollment criteria, comparator arms, and dosing schedules ^{[3] [4] [5]}. Those registrations are public and worth reading if you want the real design details, but registration on ClinicalTrials.gov is not the same thing as FDA approval. It just means a trial happened or is happening. | Trial | Registration | Top studied dose | Result reported |

Can a doctor legally prescribe retatrutide right now?

No. Under 21 U.S.C. 355, a new drug can't be introduced into interstate commerce without an FDA-approved application, and retatrutide has none ^{[1] [6]}. That's the same statute that keeps every unapproved drug off pharmacy shelves, not a retatrutide-specific rule. The only lawful way to receive retatrutide today is enrollment in one of its registered clinical trials, where dosing is fixed by protocol, monitored by investigators, and reviewed by an institutional ethics board. Outside that setting, no physician, nurse practitioner, or compounding pharmacist can write you a prescription for it, full stop. If someone is offering to "prescribe" or "guide your dosing" for retatrutide outside a trial, that's not a service grounded in any lawful pathway.

Is retatrutide on the FDA's compounding bulk substances list?

No. The complete final 503A Bulks List contains exactly six substances: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, and thymol iodide ^[7]. No peptide is on that list, and retatrutide isn't one of the six. FDA also keeps a separate, broader nominations list tracking which bulk substances have been proposed for 503A compounding and where they sit in interim review categories. Retatrutide doesn't appear there either ^{[8] [9]}. The parallel list governing outsourcing facilities under 503B, at 21 CFR 216.24, also excludes it ^[10]. In July 2026, FDA's Pharmacy Compounding Advisory Committee met to weigh seven other peptides for the bulks list: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), semax, and epitalon ^[11]. Retatrutide wasn't among them and has never been nominated for that list at all ^[11]. Even if it had been discussed, a favorable committee vote wouldn't create a compounding pathway on its own. Advisory committee recommendations are non-binding, and actually adding a substance to the Bulks List requires formal notice-and-comment rulemaking ^[11].

Why can't a compounding pharmacy just make retatrutide anyway?

Section 503A lays out a strict, ordered cascade for what a compounder can legally use as a bulk substance, and retatrutide fails every step of it ^[12]. First: does the substance comply with an applicable USP or National Formulary monograph? Retatrutide has none. Second, only if no monograph exists: is it a component of an FDA-approved drug? It isn't, since nothing containing retatrutide is approved. Third, only if neither of the first two applies: is it on the 503A Bulks List? It's not, as covered above ^[7]. The statute is explicit that compounding may draw from the Bulks List only when there's no applicable monograph and the substance isn't a component of an approved drug ^[12]. Retatrutide satisfies zero of the three branches, so there is no legal opening for a compounding pharmacy to make it, regardless of demand. There's a second, independent requirement that would sink it anyway even if the ingredient cascade weren't a problem. Every bulk drug substance used in 503A compounding has to come from a facility registered under FD&C Act section 510, accompanied by a valid certificate of analysis ^[12]. Research-use-only material sold by unregistered peptide suppliers, which is where most gray-market retatrutide originates, fails this requirement independent of the monograph issue. Two separate legal failures, either one fatal on its own.

Does a "research use only" label make gray-market retatrutide legal to buy?

No, and FDA has said so directly. Intended use of a product is determined by its labeling claims, advertising, and statements made by the seller, not by a disclaimer buried in the fine print ^[13]. That's the standard under 21 CFR 201.128, and it applies to peptides exactly the way it applies to any other product marketed with health claims ^[13]. In a March 2026 warning letter to Gram Peptides, FDA wrote that despite "research use only" and "not for human consumption" labeling, the company's own website established that its products, including retatrutide, were intended to be used as drugs by humans ^[1]. FDA's letter states that "evidence from the company's website established that its products were intended to be drugs for human use" ^[1]. The disclaimer didn't matter once the marketing copy made therapeutic or structure-function claims. That's the pattern across this whole market. A vial can say "not for human use" in ten-point font while the same site's homepage talks about weight loss, appetite suppression, and body composition. FDA looks at the second thing, not the first, when deciding whether a product is being sold as an unapproved drug. If you're evaluating a vendor and trying to decide whether the RUO language means anything, the honest answer is: not if the rest of the page reads like a weight loss pitch. For more on what makes a seller's offer illegal regardless of labeling, see our breakdown on retatrutide's legal status.

Is it dangerous to guess a dose from vendor material?

Yes, for reasons that go beyond "it's not FDA-approved." Research-use-only vials don't come with a certificate of analysis you can trust, don't guarantee sterile manufacturing, and don't guarantee the labeled concentration is what's actually in the vial ^[12]. If the concentration is wrong, every unit-based calculation built on top of it is wrong too, silently. Add to that the fact that the trial dosing that produced the 24.2% weight loss figure involved gradual titration over weeks, under monitoring for the gastrointestinal, pancreatic, and other effects that come with a triple agonist hitting GIP, GLP-1, and glucagon receptors at once ^{[2] [3]}. Jumping to a dose based on a forum post or a vendor's suggested chart skips every safety mechanism the actual trial had in place: bloodwork, titration pacing, and a clinician watching for problems. For a fuller rundown of what adverse effects showed up in trials and what's been reported anecdotally outside them, see our retatrutide side effects piece.

How is retatrutide different from semaglutide and tirzepatide, and does that change dosing?

Retatrutide is a triple agonist, acting at GIP, GLP-1, and glucagon receptors together, which mechanistically separates it from semaglutide (GLP-1 only) and tirzepatide (GIP and GLP-1) ^[2]. That third receptor, glucagon, is part of why researchers are watching retatrutide for effects on energy expenditure and liver fat, more than appetite. But the mechanistic difference is exactly why you can't safely extrapolate a semaglutide or tirzepatide dosing schedule onto retatrutide, or vice versa. Different receptor profile, different titration curve, different side effect balance. Semaglutide is approved and marketed as Ozempic and Wegovy; tirzepatide as Mounjaro and Zepbound ^[14]. Those products have FDA-reviewed dosing schedules built from their own trial programs, not borrowed from retatrutide's. If your actual goal is a GLP-1-class medication you can obtain and use under medical supervision today, those approved drugs, plus the newer oral option below, are where a licensed prescriber can actually help you, not an extrapolated retatrutide unit count.

Is there now an approved oral alternative instead of chasing retatrutide?

Yes. Orforglipron, an oral GLP-1 receptor agonist, was approved under the brand name Foundayo (NDA 220934) in six strengths ranging from 0.8 mg to 17.2 mg ^[15]. That gives patients an FDA-approved oral incretin option, with a real label, real dosing instructions, and real pharmacovigilance behind it, as an alternative to seeking out investigational compounds with no such structure. If part of retatrutide's appeal was avoiding needles, Foundayo is worth asking a prescriber about directly. It won't replicate retatrutide's triple-receptor mechanism or its trial-reported weight loss numbers, since it's a different drug class in effect (GLP-1 agonism only, in pill form), but it comes with an approved label instead of a guess.

What should someone actually do while retatrutide is unapproved?

Talk to a prescriber about the approved options that exist right now: semaglutide, tirzepatide, or orforglipron, all of which have FDA-reviewed dosing and monitoring built in ^{[14] [15]}. NIDDK, the federal government's diabetes and digestive disease institute, publishes plain-language guidance on evidence-based weight management approaches, useful as a neutral starting point while you're sorting out what's actually available to you ^[16]. If you want to track retatrutide's trial progress out of genuine research interest, that's reasonable, and ClinicalTrials.gov is the honest place to do it ^{[3] [3] [4] [5]}. Enrollment in an active trial, if you qualify and one is recruiting near you, is the only lawful way to receive the drug before approval. Buying vials online and guessing at a unit count is not a parallel path to the same outcome; it's an unregulated substance from an unregistered source, dosed by guesswork, with none of the monitoring that produced the trial numbers people are chasing.

Where does personal importation fit into this?

FDA maintains a specific policy on personal importation of unapproved drugs, and it's the actual rule that applies to anyone considering ordering an investigational compound like retatrutide from an overseas seller . The short version: FDA doesn't have to permit personal importation of an unapproved drug, and enforcement discretion in this space is narrow and unevenly applied, not a guarantee. An overseas seller marketing retatrutide with weight-loss or therapeutic claims runs into the same intended-use problem as a domestic one under 21 CFR 201.128 ^[13]. The label origin doesn't change the legal analysis; the marketing claims do.

Frequently asked questions

How many mg of retatrutide did the phase 2 trial use at the top dose?

The phase 2 obesity trial's highest studied dose was 12 mg once weekly by subcutaneous injection, reached through gradual dose escalation, not started as a first dose. It produced a mean 24.2% weight reduction at 48 weeks versus 2.1% for placebo, per the trial published in the New England Journal of Medicine ^[2].

Can I convert the trial's mg dose into insulin syringe units myself?

Doing that math requires knowing the exact reconstituted concentration, which depends on a verified milligram count and diluent volume. Gray-market vials lack a certificate of analysis confirming that count, so any unit conversion built on an unverified vial is a guess layered on top of another guess, not a real dose.

Is retatrutide legal to buy from a peptide vendor if it says 'research use only'?

No. FDA has stated that a research-use-only or not-for-human-consumption disclaimer doesn't defeat drug status when a seller's website carries therapeutic or structure-function claims. Intended use comes from labeling, advertising, and seller statements, not the disclaimer text, per 21 CFR 201.128 ^[15][16].

Why isn't retatrutide on the FDA's compounding bulks list?

The 503A Bulks List has exactly six substances (Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, thymol iodide), none of them a peptide ^[5]. Retatrutide has never been nominated for it and doesn't appear on FDA's broader nominations tracking document either ^[10][11].

Could a compounding pharmacy legally make retatrutide for me?

No. Section 503A requires a bulk substance to comply with a USP/NF monograph, or be a component of an approved drug, or appear on the Bulks List. Retatrutide meets none of the three, and separately, most gray-market retatrutide comes from unregistered suppliers without valid certificates of analysis ^[13][14].

Did FDA ever consider adding retatrutide to the compounding list?

No. FDA's Pharmacy Compounding Advisory Committee met in July 2026 to discuss seven other peptides (BPC-157, KPV, TB-500, MOTS-c, emideltide, semax, epitalon) for the bulks list. Retatrutide wasn't among them and has never been formally nominated ^[6].

What's the difference between retatrutide, semaglutide, and tirzepatide dosing?

They're not interchangeable. Retatrutide is a triple agonist (GIP, GLP-1, glucagon); tirzepatide hits GIP and GLP-1; semaglutide hits GLP-1 alone ^[2]. Semaglutide and tirzepatide have FDA-approved dosing schedules (Ozempic, Wegovy, Mounjaro, Zepbound); retatrutide has none, so no dose from one drug transfers safely to another ^[17].

Is there an FDA-approved pill alternative to retatrutide now?

Yes. Orforglipron, an oral GLP-1 agonist, was approved as Foundayo (NDA 220934) in six strengths from 0.8 mg to 17.2 mg ^[18]. It's a different mechanism than retatrutide and won't match its trial-reported results, but it's a real, prescribable, approved option today.

Can a doctor prescribe retatrutide off-label?

No. Off-label prescribing applies to approved drugs used outside their labeled indication. Retatrutide has zero FDA approvals for any indication, so there's no approved product a doctor could prescribe off-label from. The only lawful access route is enrollment in an active registered clinical trial ^[1][9].

Is it legal to personally import retatrutide from another country?

FDA's personal importation policy governs this, and it doesn't guarantee entry of unapproved drugs; enforcement discretion is narrow and case-by-case, not a right ^[20]. Marketing claims on the overseas seller's site still trigger the same intended-use analysis under 21 CFR 201.128 that applies domestically ^[15].

What trials is retatrutide currently registered in?

Public ClinicalTrials.gov records include the original phase 2 obesity trial (NCT04881760) and later-phase trials (NCT05929066 and NCT05882045), plus registered type 2 diabetes studies. Each listing states its own enrollment criteria, comparators, and dosing schedule, worth reading directly if you're considering enrollment ^[3][4][7][8].

What actually determines if a peptide seller is operating illegally?

Not the disclaimer. FDA looks at labeling claims, advertising, and statements by the seller to establish intended use under 21 CFR 201.128. A March 2026 warning letter to Gram Peptides cited retatrutide marketing specifically, despite research-use-only language on the site ^[15][16].

Sources

1. Drugs@FDA, FDA-approved drug products database: A search for the generic name retatrutide returns no FDA-approved product
2. Jastreboff AM et al., New England Journal of Medicine, 2023: Phase 2 trial: 12 mg retatrutide produced 24.2% mean weight loss at 48 weeks vs 2.1% placebo; retatrutide is a GIP/GLP-1/glucagon triple agonist
3. ClinicalTrials.gov, NCT04881760: Registration record for the phase 2 obesity trial of LY3437943 (retatrutide), listing dose arms and route studied
4. 21 CFR 216.23, eCFR: The complete final 503A Bulks List contains exactly six substances, none a peptide, and retatrutide is not among them
5. Federal Register, Docket FDA-2025-N-6895, published 16 April 2026: July 2026 Pharmacy Compounding Advisory Committee meeting considered seven other peptides, not retatrutide; advisory votes are non-binding and adding to the Bulks List requires rulemaking
6. ClinicalTrials.gov, NCT05929066: Later-phase retatrutide trial registration listing enrollment criteria, comparators, and endpoints
7. ClinicalTrials.gov, NCT05882045: Second later-phase retatrutide trial registration record
8. 21 U.S.C. 355: A new drug cannot be introduced into interstate commerce without an FDA-approved application
9. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: Public list of bulk substances nominated for 503A compounding; retatrutide does not appear on it
10. FDA, Bulk Drug Substances Nominated for Use in Compounding (PDF): Authoritative roster of Category 1, 2, and 3 nominated substances as of its stated revision date
11. 21 CFR 216.24, eCFR: The separate 503B outsourcing facility bulks list also does not include retatrutide
12. 21 U.S.C. 353a(b)(1)(A)(i): 503A's ingredient cascade requires monograph compliance, then component-of-approved-drug status, then Bulks List inclusion, in that order
13. 21 CFR 201.128: Intended use is established by labeling claims, advertising, and seller statements, not by disclaimers
14. Drugs@FDA, NDA 220934 record: Orforglipron was approved as Foundayo under NDA 220934 in six strengths from 0.8 mg to 17.2 mg
15. NIDDK, Weight Management: Federal guidance on evidence-based weight management as a neutral reference while retatrutide remains unapproved
16. FDA, Personal Importation: FDA's policy governing personal importation of unapproved drugs, including narrow and discretionary enforcement